Drug Information

Drug (ID: DG00392) and It's Reported Resistant Information

• Name: Microcin J25
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (3 diseases)
  Escherichia coli intestinal infection [ICD-11: 1A03]; [1]
  Salmonellosis [ICD-11: 1A09]; [1]
  Shigellosis [ICD-11: 1A02]; [1]
• Formula: C101H139N23O27
• IsoSMILES: CC[C@H](C)[C@H]1C(=NCC(=N[C@H](C(=O)N2CCC[C@H]2C(=N[C@H](C(=N[C@H](C(=N[C@H](C(=N[C@H](C(=NCC(=NCC(=NCC(=N[C@H](C(=NCC(=N[C@H](C(=N[C@H](C(=O)N3CCC[C@H]3C(=N[C@H](C(=N[C@H](C(=N[C@H](C(=N[C@H](C(=NCC(=N1)O)O)C(C)C)O)CC4=CC=CC=C4)O)CC5=CC=C(C=C5)O)O)CCC(=O)O)O)C(C)C)O)CC6=CN=CN6)O)O)C)O)O)O)O)CC7=CC=C(C=C7)O)O)CC8=CC=CC=C8)O)CO)O)[C@@H](C)CC)O)[C@@H](C)O)O)O
• InChI: 1S/C101H139N23O27/c1-11-55(7)84-98(148)108-50-80(134)119-86(58(10)126)101(151)124-38-20-26-74(124)96(146)122-85(56(8)12-2)99(149)117-72(51-125)94(144)116-68(39-59-21-15-13-16-22-59)90(140)113-67(41-61-27-31-64(127)32-28-61)88(138)106-46-76(130)103-45-75(129)104-47-77(131)110-57(9)87(137)105-48-78(132)111-71(43-63-44-102-52-109-63)93(143)121-83(54(5)6)100(150)123-37-19-25-73(123)95(145)112-66(35-36-81(135)136)89(139)114-69(42-62-29-33-65(128)34-30-62)91(141)115-70(40-60-23-17-14-18-24-60)92(142)120-82(53(3)4)97(147)107-49-79(133)118-84/h13-18,21-24,27-34,44,52-58,66-74,82-86,125-128H,11-12,19-20,25-26,35-43,45-51H2,1-10H3,(H,102,109)(H,103,130)(H,104,129)(H,105,137)(H,106,138)(H,107,147)(H,108,148)(H,110,131)(H,111,132)(H,112,145)(H,113,140)(H,114,139)(H,115,141)(H,116,144)(H,117,149)(H,118,133)(H,119,134)(H,120,142)(H,121,143)(H,122,146)(H,135,136)/t55-,56-,57-,58+,66-,67-,68-,69-,70-,71-,72-,73-,74-,82-,83-,84-,85-,86-/m0/s1
• InChIKey: TVZWTTNULXZYTK-UBTJVNBSSA-N
• PubChem CID: 101038823

Type(s) of Resistant Mechanism of This Drug

  IDUE: Irregularity in Drug Uptake and Drug Efflux

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

Shigellosis [ICD-11: 1A02]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: ABC transporter ATP-binding/permease protein YojI (YOJI) [1]

• Molecule Alteration: Expression; Inherence
• Resistant Disease: Shigella intestinal infection [ICD-11: 1A02.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Escherichia coli k-12; 83333
• Experiment for Molecule Alteration: Promega and one-step chromosomal gene inactivation method assay
• Experiment for Drug Resistance: Spot-on-lawn assay
• Mechanism Description: YojI, an Escherichia coli open reading frame with an unknown function, mediates resistance to the peptide antibiotic microcin J25 when it is expressed from a multicopy vector. Disruption of the single chromosomal copy of yojI increased sensitivity of cells to microcin J25. One obvious explanation for the protective effect against microcin J25 is that YojI action keeps the intracellular concentration of the peptide below a toxic level. the resistance to MccJ25 mediated by YojI involves extrusion of the peptide and that YojI is assisted by the multifunctional outer membrane protein TolC.

Escherichia coli intestinal infection [ICD-11: 1A03]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: ABC transporter ATP-binding/permease protein YojI (YOJI) [1]

• Molecule Alteration: Expression; Inherence
• Resistant Disease: Escherichia coli infection [ICD-11: 1A03.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Escherichia coli k-12; 83333
• Experiment for Molecule Alteration: Promega and one-step chromosomal gene inactivation method assay
• Experiment for Drug Resistance: Spot-on-lawn assay
• Mechanism Description: YojI, an Escherichia coli open reading frame with an unknown function, mediates resistance to the peptide antibiotic microcin J25 when it is expressed from a multicopy vector. Disruption of the single chromosomal copy of yojI increased sensitivity of cells to microcin J25. One obvious explanation for the protective effect against microcin J25 is that YojI action keeps the intracellular concentration of the peptide below a toxic level. the resistance to MccJ25 mediated by YojI involves extrusion of the peptide and that YojI is assisted by the multifunctional outer membrane protein TolC.

Salmonellosis [ICD-11: 1A09]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: ABC transporter ATP-binding/permease protein YojI (YOJI) [1]

• Molecule Alteration: Expression; Inherence
• Resistant Disease: Salmonella enterica infection [ICD-11: 1A09.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Escherichia coli k-12; 83333
• Experiment for Molecule Alteration: Promega and one-step chromosomal gene inactivation method assay
• Experiment for Drug Resistance: Spot-on-lawn assay
• Mechanism Description: YojI, an Escherichia coli open reading frame with an unknown function, mediates resistance to the peptide antibiotic microcin J25 when it is expressed from a multicopy vector. Disruption of the single chromosomal copy of yojI increased sensitivity of cells to microcin J25. One obvious explanation for the protective effect against microcin J25 is that YojI action keeps the intracellular concentration of the peptide below a toxic level. the resistance to MccJ25 mediated by YojI involves extrusion of the peptide and that YojI is assisted by the multifunctional outer membrane protein TolC.

References

• Ref 1: YojI of Escherichia coli functions as a microcin J25 efflux pump. J Bacteriol. 2005 May;187(10):3465-70. doi: 10.1128/JB.187.10.3465-3470.2005.